GMAB — Genmab A/S
$51.37
$-0.37 (-0.72%)
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Market Cap
$31.67B
Forward P/E
32.5x
52-Week Range
N/A
GMAB Price History
Revenue vs. Net Income
$23.5B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$1.1B
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
11.1%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.8x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.2%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-3.0%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
